Portal de Periódicos da CAPES

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

2024; Massachusetts Medical Society; Volume: 391; Issue: 1 Linguagem: Inglês

10.1056/nejmoa2313811

1533-4406

Ignace Vergote, Antonio González‐Martín, Keiichi Fujiwara, Elsa Kalbacher, Andrea Bagaméri, Sharad Ghamande, Jung‐Yun Lee, Susana Banerjee, Fernando Cotait Maluf, Domenica Lorusso, Kan Yonemori, Els Van Nieuwenhuysen, Luís Manso, Linn Woelber, Anneke M. Westermann, Allan Covens, Kosei Hasegawa, Byoung‐Gie Kim, Miriam Raimondo, Maria Bjurberg, Felipe Melo Cruz, Antoine Angelergues, David Cibula, Lisa Barraclough, Ana Oaknin, Christine Gennigens, L. Nicacio, Melinda Siew Leng Teng, Elizabeth Whalley, Ibrahima Soumaoro, Brian M. Slomovitz,

Lung Cancer Treatments and Mutations

Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy.